≥98%HPLC Purity
COAIncluded
USAShipped
Melanotan I Peptide
Linear alpha-MSH analog peptide (Afamelanotide). Studied for MC1R receptor selectivity and melanocortin pathway research.
Login to view pricing and purchase
Create a free account to see prices, select variants, and place orders.
Log In / Create AccountQuick Facts
| SKU | ACR-MT1 |
|---|---|
| CAS Number | 75921-69-6 |
| Molecular Weight | 1646.85 g/mol |
| Sequence | [Nle4, D-Phe7]-alpha-MSH |
| Purity | ≥98% |
| Physical Form | Lyophilized Powder |
| Storage | Store at -20°C |
What is Melanotan I?
Melanotan I (afamelanotide, MT-1) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) with 13 amino acids. Unlike Melanotan II, MT-1 is a linear peptide (not cyclic) and is more selective for the MC1R melanocortin receptor. It has been extensively studied for its role in melanogenesis — the production of melanin pigment in the skin.
Mechanism of Action
Melanotan I binds primarily to MC1R (melanocortin-1 receptor) on melanocytes, activating the cAMP/PKA/CREB signaling cascade. This upregulates MITF (microphthalmia-associated transcription factor), which in turn increases expression of tyrosinase, TRP-1, and TRP-2 — the key enzymes in eumelanin biosynthesis.
The result is increased eumelanin production without requiring UV exposure, a property that has made MT-1 the subject of extensive dermatological and photoprotection research.
Frequently Asked Questions
What is the difference between Melanotan I and Melanotan II?
Melanotan I (afamelanotide) is a linear 13-amino acid peptide selective for MC1R. Melanotan II is a cyclic 7-amino acid peptide that activates multiple melanocortin receptors (MC1R, MC3R, MC4R, MC5R), giving it broader effects beyond melanogenesis.
What receptor does Melanotan I target?
Melanotan I primarily targets MC1R (melanocortin-1 receptor) on melanocytes, activating the cAMP signaling pathway to stimulate eumelanin production.
For laboratory and research use only. Not intended for human or animal consumption. All product information is derived from published preclinical research and does not constitute medical advice or claims.